Glaucoma is an optic neuropathy characterized by death of retinal ganglion cells (RGCs), which leads to progressive visual field loss and may result in blindness. Currently, the only available treatment to avoid or delay progression in glaucoma patients is to decrease intraocular pressure (IOP). However, despite adequate IOP control, approximately 25% of the patients continue to progress. To delay or prevent optic nerve damage in glaucoma, two forms of vitamin B3, nicotinamide (NAM) and nicotinamide riboside (NR) are emerging as viable adjuvant therapies. These compounds are nicotinamide adenine dinucleotide (NAD) precursors. NAD is essential for proper cell functioning and is involved in several metabolic activities, including protection against reactive oxygen species, contribution to the performance of various enzymes, and maintenance of mitochondrial function. Due to its beneficial effects and to the evidence of the reduction of NAD bioavailability with aging, researchers are seeking ways to replenish the cellular NAD pool, by administrating its precursors (NAM and NR), believing that it will reduce the RGC vulnerability to external stressors, such as increased IOP. This article attempts to analyze the current knowledge regarding the use of NAM and NR for the prevention and/or treatment of glaucoma.
HarasymowyczPBirtCGooiP, et al.Medical Management of Glaucoma in the 21st Century from a Canadian Perspective. J Ophthalmol2016; 2016: 1–22.
2.
JonasJBAungTBourneRR, et al.Glaucoma. The Lancet2017; 390: 2183–2193.
3.
BourneRRAStevensGAWhiteRA, et al.Causes of vision loss worldwide, 1990–2010: A systematic analysis. Lancet Glob Health2013; 1: e339–e349.
4.
StevensGAWhiteRAFlaxmanSR, et al.Global prevalence of vision impairment and blindness: magnitude and temporal trends, 1990–2010. Ophthalmology2013; 120: 2377–2384.
5.
ThamYCLiXWongTY, et al.Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology2014; 121: 2081–2090.
6.
PrumBERosenbergLFGeddeSJ, et al.Primary open-angle glaucoma. Ophthalmology2016; 123: P41–111.
7.
HeijlACristina LeskeMBengtssonB, et al.Reduction of intraocular pressure and glaucoma progression results from the early manifest glaucoma trial. Arch Ophthalmol2002; 120: 1268–1279.
8.
Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol1998; 126: 498–505.
9.
The AGIS investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol2000; 130: 429–440.
10.
MelchiorBde MoraesCGPaulaJS, et al.Relationship between mean follow-up intraocular pressure, rates of visual field progression and current target intraocular pressure guidelines. Br J Ophthalmol2020; 106: 229–233.
11.
Garway-HeathDFCrabbDPBunceC, et al.Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. The Lancet2015; 385:1295–1304.
12.
AlmasiehMWilsonAMMorquetteB. Cueva, et al.The molecular basis of retinal ganglion cell death in glaucoma. Prog Retin Eye Res2012; 31: 152–181.
13.
GazzardGKonstantakopoulouEGarway-HeathD, et al.Laser in Glaucoma and Ocular Hypertension Trial: Six-Year Results of Primary Selective Laser Trabeculoplasty versus Eye Drops for the Treatment of Glaucoma and Ocular Hypertension. Ophthalmology2022; 130: 139–151.
14.
CaprioliJ.Neuroprotection of the optic nerve in glaucoma. Acta Ophthalmol Scand1997; 75: 364–367.
15.
GeorgopoulosGAndreanosDLlokisN, et al.Risk factors in ocular hypertension. Eur J Ophthalmol1997; 7: 357–363.
16.
ChauhanBCMikelbergFSGordon BalasziA, et al.Canadian Glaucoma study 2. Risk factors for the progression of open-angle glaucoma. Arch Ophthalmol [Internet]2008; 126: 1030–1036. Available from: http://www.archophthalmol.com]
RamdasWDSchoutenJSAGWebersCAB.The effect of vitamins on glaucoma: A systematic review and meta-analysis. Nutrients2018;10: 1–14.
19.
ColemanALStoneKLKodjebachevaG, et al.Glaucoma risk and the consumption of fruits and vegetables among older women in the study of osteoporotic fractures. Am J Ophthalmol2008; 145: 1081–1089.
20.
GiaconiJAYuFStoneKL, et al.The association of consumption of fruits/vegetables with decreased risk of glaucoma among older African-American women in the study of osteoporotic fractures. Am J Ophthalmol2012; 154: 635–644.
21.
MorroneLARombolaLAdornettoA, et al.Rational basis for nutraceuticals in the treatment of glaucoma. Curr Neuropharmacol2018; 16: 1004–1017.
22.
Pinazo-DuranMDShoaie-NiaKZanon-MorenoV, et al.Strategies to reduce oxidative stress in glaucoma patients. Curr Neuropharmacol2017; 16: 903–918.
23.
ScuteriDRombolàLWatanabeC, et al.Impact of nutraceuticals on glaucoma: a systematic review. Prog Brain Res2020; 257: 141–154.
24.
JabbehdariSChenJLVajaranantTS.Effect of dietary modification and antioxidant supplementation on intraocular pressure and open-angle glaucoma. Eur J Ophthalmol2021; 31: 1588–1605.
25.
LoskutovaEO’BrienCLoskutovI, et al.Nutritional supplementation in the treatment of glaucoma: a systematic review. Surv Ophthalmol2019; 64: 195–216.
26.
SachdevaVRoyABharadvajaN.Current prospects of nutraceuticals: a review. Curr Pharm Biotechnol2020; 21: 884–896.
27.
DepeintFBruceWRShangariN, et al.Mitochondrial function and toxicity: role of the B vitamin family on mitochondrial energy metabolism. Chem Biol Interact2006; 163: 94–112.
28.
CaoGLBoothSASadowskiJL, et al.Increases in human plasma antioxidant capacity after consumption of controlled diets high in fruit and vegetables. Am J Clin Nutr1998; 68: 1081–1087.
29.
Romeo VilladónigaSRodríguez GarcíaESagastagoia EpeldeO,et al.Effects of oral supplementation with docosahexaenoic acid (DHA) plus antioxidants in pseudoexfoliative glaucoma: A 6-Month open-label randomized trial. J Ophthalmol2018; 2018: 1–8.
30.
AdornettoARombolàLMorroneLA, et al.Natural products: evidence for neuroprotection to be exploited in glaucoma. Nutrients2020; 12: 1–33.
31.
WilliamsPAHarderJMJohnSWM.Glaucoma as a metabolic optic neuropathy: making the case for nicotinamide treatment in glaucoma. J Glaucoma2017; 26: 1161–1168.
32.
ZhangXZhangNChrenekMA, et al.Systemic treatment with nicotinamide riboside is protective in two mouse models of retinal ganglion cell damage. Pharmaceutics2021; 13: 1–16.
33.
WilliamsPAHarderJMFoxworthNE, et al.Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice. Science (1979)2017; 355: 756–760.
34.
HuiFTangJWilliamsPA, et al.Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: a crossover randomized clinical trial. Clin Exp Ophthalmol2020; 48: 903–914.
35.
TaechameekietichaiTChansangpetchSPeerawaranunP, et al.Association between daily niacin intake and glaucoma: National health and nutrition examination survey. Nutrients2021; 13: 1–13.
36.
KnipMDouekIMooreW, et al.Safety of high-dose nicotinamide: a review. Diabetologia [Internet]2000[cited 2021 Oct 25]; 43: 1337–1345. Available from: https://pubmed.ncbi.nlm.nih.gov/11126400/
37.
MorabiaA.Joseph goldberger’s research on the prevention of pellagra. J R Soc Med [Internet]2008Nov 1 [cited 2021 Oct 25]; 101: 566–568. Available from: https://pubmed.ncbi.nlm.nih.gov/19029358/
38.
PenberthyWTKirklandJB.Niacin. Tenth. ErdmanJWJrMacdonaldIAZeiselSH (eds) editors. New Jersey, USA: John Wiley & Sons, Inc.; 2012, pp. 293–306.
RolfeHM.A review of nicotinamide: treatment of skin diseases and potential side effects. J Cosmet Dermatol2014; 13: 324–328.
41.
FrickerRAGreenELJenkinsSI, et al.The influence of nicotinamide on health and disease in the central nervous system. Int J Tryptophan Res2018; 11: 1–11.
42.
MarcusRCoulstonAM.Water-soluble vitamins. The vitamin B complex and ascorbic acid. In: Goodman & Gilman’s the pharmacological basis of therapeutics. 9th ed. Newyork: Mc grawhill, 1996, pp.1555–1571. Available from: https://www.scienceopen.com/document?vid=31942b71-76d5-4aa1-a671-e696c22aaf00.
43.
WilliamsARamsdenD.Nicotinamide: a double edged sword. Parkinsonism Relat Disord2005; 11: 413–420.
44.
National Academies Press (US). Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and Choline. 1998.
45.
MaieseKChongZZHouJ, et al.The vitamin nicotinamide: translating nutrition into clinical care. Molecules2009; 14: 3446–3485.
46.
GreenKNSteffanJSMartinez-CoriaH, et al.Nicotinamide restores cognition in Alzheimer’s disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci2008; 28: 11500–11510.
47.
NaiaLRosenstockTROliveiraAM, et al.Comparative mitochondrial-based protective effects of resveratrol and nicotinamide in huntington’s disease models. Mol Neurobiol2017; 54: 5385–5399.
48.
WangPMiaoCY.NAMPT As a therapeutic target against stroke. Trends Pharmacol Sci2015; 36: 891–905.
49.
AndersonDWBradburyKASchneiderJS.Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism. Eur J Neurosci2008; 28: 610–617.
50.
MokudaiTAyoubIASakakibaraY, et al.Delayed treatment with nicotinamide (vitamin B 3) improves neurological outcome and reduces infarct volume after transient focal cerebral ischemia in wistar rats. Stroke [Internet]2000; 31: 1679–1685. Available from: http://www.strokeaha.org
51.
SongSBParkJSChungGJ, et al.Diverse therapeutic efficacies and more diverse mechanisms of nicotinamide. Metabolomics2019; 15: 1–28.
52.
TsujitaNAkamatsuYMakoto NishidaM, et al.Effect of tryptophan, vitamin B 6, and nicotinamide-containing supplement loading between meals on mood and autonomic nervous system activity in young adults with subclinical depression: a randomized, double-blind, and placebo-controlled study. J Nutr Sci Vitaminol [Internet]2019; 65: 507–514. Available from: http://www.fsc.go.jp/
53.
Handfield-JonesSJonesSPeacheyR.High dose nicotinamide in the treatment of necrobiosis lipoidica. Br J Dermatol1988; 118: 693–696.
54.
MaAMedenicaM.Response of generalized granuloma Annulare to high-dose niacinamide. Arch Dermatol [Internet]1983; 119: 836–839. Available from: http://archderm.jamanetwork.com/
55.
NeumannRRappoldEPohl-MarklH.Pharmacology and treatment treatment of polymorphous light eruption with nicotinamide: a pilot study. Br J Dermatol1986; 115: 77–80.
56.
ReicheLWojnarowskaFMallonE.Combination therapy with nicotinamide and tetracyclines for cicatricial pemphigoid: further support for its efficacy. Clin Exp Dermatol1998; 23: 254–257.
57.
StarrP.Oral nicotinamide prevents common skin cancers in high-risk patients, reduces costs. Am Health Drug Benefits2015; 8: 13–14.
58.
DamianDLPattersonCRSStapelbergM, et al.UV radiation-induced immunosuppression is greater in men and prevented by topical nicotinamide. J Invest Dermatol2008; 128: 447–454.
59.
FivensonDPBrenemanDLRosenGB, et al.Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol [Internet]1994; 130: 753–758. Available from: http://archderm.jamanetwork.com/
60.
ForbatEAl-NiaimiFAliFR.Use of nicotinamide in dermatology. Clin Exp Dermatol2017; 42: 137–144.
61.
NamaziMR.Nicotinamide: a potential addition to the anti-psoriatic weaponry. FASEB J2003; 17: 1377–1379.
62.
BadawyAAB. Bioscience Reports2020; 40: 1–18.
63.
ElliottRBChaseHP.Prevention or delay of type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide. Diabetologia1991; 34: 362–365.
64.
ElliottRBPilcherCCFergussonDM, et al.A population based strategy to prevent insulin-dependent diabetes using nicotinamide. London Journal of Pediatric Endocrinology & Metabolism1996; 9: 501–509.
65.
LampeterEFKlinghammerAScherbaumWA, et al.The deutsche nicotinamide intervention study an attempt to prevent type 1 diabetes. Diabetes1998; 47: 980–984.
66.
BieganowskiPBrennerC.Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a preiss-handler independent route to NAD in fungi and humans. Cell2004; 117: 495–502.
67.
BelenkyPRacetteFGBoganKL, et al.Nicotinamide riboside promotes Sir2 silencing and extends lifespan via nrk and Urh1/Pnp1/Meu1 pathways to NAD+. Cell2007; 129: 473–484.
68.
BoganKLBrennerC.Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu Rev Nutr2008; 28: 115–130.
69.
PoddarSKSifatAEHaqueS, et al.Nicotinamide mononucleotide: Exploration of diverse therapeutic applications of a potential molecule. Biomolecules2019; 9: 1–15.
70.
TrammellSAJSchmidtMSWeidemannBJ, et al.Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun2016; 7: 1–14.
71.
TrammellSAJWeidemannBJChaddaA, et al.Nicotinamide riboside opposes type 2 diabetes and neuropathy in mice. Sci Rep2016; 6: 1–7.
72.
CantóCHoutkooperRHPirinenE, et al.The NAD+ precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab2012; 15: 838–847.
73.
MehmelMJovanovićNSpitzU.Nicotinamide riboside—the current state of research and therapeutic uses. Nutrients2020; 12: 1–22.
74.
DiguetNTrammellSAJTannousC, et al.Nicotinamide riboside preserves cardiac function in a mouse model of dilated cardiomyopathy. Circulation2018; 137: 2256–2273.
75.
VaurPBruggBMericskayM, et al.Nicotinamide riboside, a form of vitamin B3, protects against excitotoxicity-induced axonal degeneration. FASEB J2017; 31: 5440–5452.
76.
GongBPanYVempatiP, et al.Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-γ coactivator 1α regulated β-secretase 1 degradation and mitochondrial gene expression in Alzheimer’s mouse models. Neurobiol Aging2013; 34: 1581–1588.
77.
CovarrubiasAJPerroneRGrozioA, et al.NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol2021; 22: 119–141.
78.
ImaiSGuarenteL.NAD+ and sirtuins in aging and disease. Trends Cell Biol2014; 24: 464–471.
79.
KatsyubaERomaniMHoferD, et al.NAD+ homeostasis in health and disease. Nat Metab2020; 2: 9–31.
80.
MakarovMvTrammellSAJMigaudME.The chemistry of the vitamin B3 metabolome. Biochem Soc Trans2018; 47: 131–147.
81.
SaharSNinVBarbosaMT, et al.Altered behavioral and metabolic circadian rhythms in mice with disrupted NAD+ oscillation. Aging (Albany NY)2011; 3: 794–802.
82.
CantóCMenziesKJAuwerxJ.NAD+ metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab2015; 22: 31–53.
83.
CimagliaGVotrubaMMorganJE, et al.Potential therapeutic benefit of nad+ supplementation for glaucoma and age-related macular degeneration. Nutrients2020; 12: 1–21.
84.
CarafaVRotiliDForgioneM, et al.Sirtuin functions and modulation: from chemistry to the clinic. Clin Epigenetics2016; 8: 1–22.
85.
YangJKlaidmanLKNalbandianA, et al.The effects of nicotinamide on energy metabolism following transient focal cerebral ischemia in wistar rats. Neurosci Lett [Internet]2002; 333: 91–94. Available from: www.elsevier.com/locate/neulet
86.
ChongZLinSMaieseK.Nicotinamide modulates mitochondrial membrane potential and cysteine protease activity during cerebral vascular endothelial cell injury. J Vasc Res [Internet]2002; 39: 131–147. Available from: www.karger.comwww.karger.com/journals/jvr
87.
LinSHChongZZMaieseK.Nicotinamide: A Nutritional Supplement that Provides Protection Against Neuronal and Vascular Injury. J Med Food2001; 4: 27–38.
88.
BonkowskiMSSinclairDA.Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds. Nat Rev Mol Cell Biol2016; 17: 679–690.
89.
NickellsRW.The cell and molecular biology of glaucoma: mechanisms of retinal ganglion cell death. Invest Ophthalmol Vis Sci2012; 53: 2476–2481.
90.
KitaokaYSaseKTsukaharaC, et al.Axonal protection by nicotinamide riboside via SIRT1-autophagy pathway in TNF-induced optic nerve degeneration. Mol Neurobiol2020; 57: 4952–4960.
91.
ZhangXHennemanNFGirardotPE, et al.Systemic Treatment with Nicotinamide Riboside Is Protective in a Mouse Model of Light-Induced Retinal Degeneration. Invest Ophthalmol Vis Sci2020; 61: 1–13.
92.
SasakiYArakiTMilbrandtJ.Stimulation of nicotinamide adenine dinucleotide biosynthetic pathways delays axonal degeneration after axotomy. J Neurosci2006; 26: 8484–8491.
93.
PetritiBWilliamsPALascaratosG,et al.Neuroprotection in glaucoma: nad+/nadh redox state as a potential biomarker and therapeutic target. Cells2021; 10: 1402.
94.
FechtnerRDWeinrebRN.MAJOR REVIEW mechanisms of optic nerve damage in primary open angle glaucoma. Surv Ophthalmol1994; 39: 23–42.
95.
QuigleyHAMckinnonSJZackDJ, et al.Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats. Invest Ophthalmol Vis Sci2000; 41: 3460–3466.
96.
WeinrebRNTeePK.Primary open-angle glaucoma. Lancet [Internet]2004; 363: 1711–1720. Available from: www.thelancet.com
97.
WeinrebRNAungTMedeirosFA.The pathophysiology and treatment of glaucoma: a review. JAMA - Journal of the American Medical Association2014; 311: 1901–1911.
DreyerEBZurakowskiDSchumerRA, et al.Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Archives Of Ophthalmology [Internet]1996; 114: 299–305. Available from: http://archopht.jamanetwork.com/
100.
TezelGEdwardDPWaxMB.Serum autoantibodies to optic nerve head glycosaminoglycans in patients with glaucoma. Arch Ophthalmol. 1999;117:917–924.
NitaMGrzybowskiA.The Role of the Reactive Oxygen Species and Oxidative Stress in the Pathomechanism of the Age-Related Ocular Diseases and Other Pathologies of the Anterior and Posterior Eye Segments in Adults. Oxid Med Cell Longev2016; 2016: 1–23.
103.
LiebmannJMCioffiGA.Nicking glaucoma with nicotinamide?N Engl J Med2017; 376: 2079–2081.
104.
Lopez SanchezMIGCrowstonJGMackeyDA, et al.Emerging mitochondrial therapeutic targets in optic neuropathies. Pharmacol Ther2016; 165: 132–152.
105.
OsborneNNÁlvarezCNdel Olmo AguadoS.Targeting mitochondrial dysfunction as in aging and glaucoma. Drug Discov Today2014; 19: 1613–1622.
106.
LeeSvan BergenNJKongGY, et al.Mitochondrial dysfunction in glaucoma and emerging bioenergetic therapies. Exp Eye Res2011; 93: 204–212.
107.
TribbleJROtmaniASunS, et al.Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunction. Redox Biol2021; 43: 1–21.
108.
Cabello-VerrugioCSimonFTrolletC, et al.Oxidative Stress in Disease and Aging: Mechanisms and Therapies 2016. Oxid Med Cell Longev2017; 2017: 1–2.
109.
FinkelTHolbrookNJ.Oxidants, oxidative stress and the biology of ageing. Nature2000; 408: 239–247.
110.
RayPDHuangBWTsujiY.Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal2012; 24: 981–990.
111.
KalyanaramanB.Teaching the basics of redox biology to medical and graduate students: oxidants, antioxidants and disease mechanisms. Redox Biol2013; 1: 244–257.
112.
TezelGYangXCaiJ.Proteomic identification of oxidatively modified retinal proteins in a chronic pressure-induced rat model of glaucoma. Invest Ophthalmol Vis Sci2005; 46: 3177–3187.
113.
KoMLPengPHMaMCRitchR, et al.Dynamic changes in reactive oxygen species and antioxidant levels in retinas in experimental glaucoma. Free Radic Biol Med2005; 39: 365–373.
114.
MorenoMCCampanelliJSandeP,et al.Retinal oxidative stress induced by high intraocular pressure. Free Radic Biol Med2004; 37: 803–812.
115.
BabizhayevMABuninAY.Lipid peroxidation in open-angle glaucoma. Acta Ophthalmol1989; 67: 371–377.
116.
IzzottiASaccàSCCartigliaC, et al.Oxidative deoxyribonucleic acid damage in the eyes of glaucoma patients. Am J Med2003; 114: 638–646.
117.
SaccàSCPascottoACamicioneP, et al.Oxidative DNA damage in the human trabecular meshwork clinical correlation in patients with primary open-angle glaucoma. Arch Ophthalmol2005; 123: 458–463.
118.
IzzottiABagnisASaccàSC.The role of oxidative stress in glaucoma. Mutat Res Rev Mutat Res2006; 612: 105–114.
119.
ShenJWangYYaoK.Protection of retinal ganglion cells in glaucoma: current status and future. Exp Eye Res2021; 205: 1–13.
120.
ChrysostomouVRezaniaFTrounceIA, et al.Oxidative stress and mitochondrial dysfunction in glaucoma. Curr Opin Pharmacol2013; 13: 12–15.
121.
TezelGBen-HurTGibsonGEet al.Investigative ophthalmology and visual science2009; 50: 1001–1012.
122.
McelneaEMQuillBDochertyNG, et al.Oxidative stress, mitochondrial dysfunction and calcium overload in human lamina cribrosa cells from glaucoma donors [Internet]. 2011. Available from: http://www.molvis.org/molvis/v17/a133
123.
CammalleriMMonteMDAmatoR, et al.A dietary combination of forskolin with homotaurine, spearmint and B vitamins protects injured retinal ganglion cells in a rodent model of hypertensive glaucoma. Nutrients2020; 12: 1–19.
124.
BanerjeeDBanerjeeAMookherjeeS, et al.Mitochondrial Genome Analysis of Primary Open Angle Glaucoma Patients. PLoS One2013; 8: 1–12.
125.
Abu-AmeroKKMoralesJBosleyTM.Mitochondrial abnormalities in patients with primary open-angle glaucoma. Invest Ophthalmol Vis Sci2006; 47: 2533–2541.
126.
van BergenNJCrowstonJGCraigJE, et al.Measurement of systemic mitochondrial function in advanced Primary Open-Angle Glaucoma and leber hereditary optic neuropathy. PLoS One2015; 10: 1–18.
127.
JuWKKimKYLindseyJD, et al.Intraocular pressure elevation induces mitochondrial fission and triggers OPA1 release in glaucomatous optic nerve. Invest Ophthalmol Vis Sci2008;49: 4903–4911.
128.
LascaratosGChauKYZhuH, et al.Resistance to the most common optic neuropathy is associated with systemic mitochondrial efficiency. Neurobiol Dis2015; 82: 78–85.
129.
VerdinE.NAD + in aging, metabolism, and neurodegeneration. Science [Internet]2015; 350: 1208–1213. Available from: www.sciencemag.org
130.
ChiniCCSTarragóMGChiniEN.NAD And the aging process: role in life, death and everything in between. Mol Cell Endocrinol2017; 455: 62–74.
131.
AmanYQiuYTaoJ, et al.Therapeutic potential of boosting NAD+ in aging and age-related diseases. Transl Med Aging2018; 2: 30–37.
132.
Kouassi NzoughetJChao de la BarcaJMGuehlouzK, et al.Nicotinamide deficiency in primary open-angle glaucoma. Invest Ophthalmol Vis Sci2019; 60: 2509–2514.
133.
LiuDPittaMJiangH, et al.Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: evidence for improved neuronal bioenergetics and autophagy procession. Neurobiol Aging2013; 34: 1564–1580.
134.
PetritiBLascaratosGChauD,et al.Preliminary data show normal tension glaucoma patients have lower systemic nicotinamide adenine dinucleotide (NAD+) levels and mitochondrial function compared to controls. Invest Ophthalmol Vis Sci2021; 62: 1765.
135.
WangJHeZ.NAD And axon degeneration: from the wlds gene to neurochemistry. Cell Adh Migr [Internet]2009; 3: 77–87. Available from: www.landesbioscience.com
136.
SchöndorfDCIvanyukDBadenP, et al.The NAD+ precursor nicotinamide riboside rescues mitochondrial defects and neuronal loss in iPSC and fly models of Parkinson’s disease. Cell Rep2018; 23: 2976–2988.
137.
ChouTHRomanoGLAmatoR, et al.Nicotinamide-rich diet in dba/2j mice preserves retinal ganglion cell metabolic function as assessed by perg adaptation to flicker. Nutrients2020; 12: 1–8.
138.
HowellGRMacalinaoDGSousaGL, et al.Molecular clustering identifies complement and endothelin induction as early events in a mouse model of glaucoma. J Clin Invest2011; 121: 1429–1444.
139.
LibbyRTAndersonMGPangIH, et al.Inherited glaucoma in DBA02J mice: pertinent disease features for studying the neurodegeneration. Vis Neurosci2005; 22: 637–648.
140.
WilliamsPAHowellGRBarbayJM, et al.Retinal ganglion cell dendritic atrophy in DBA/2J glaucoma. PLoS One2013; 8: 1–10.
141.
HowellGRLibbyRTJakobsTC, et al.Axons of retinal ganglion cells are insulted in the optic nerve early in DBA/2J glaucoma. J Cell Biol2007;179:1523–1537.
142.
ReichsteinDRenLFilippopoulosT, et al.Apoptotic retinal ganglion cell death in the DBA/2 mouse model of glaucoma. Exp Eye Res2007; 84: 13–21.
143.
WilliamsPAHarderJMCardozoBH, et al.Nicotinamide treatment robustly protects from inherited mouse glaucoma. Commun Integr Biol2018; 11: 1–5.
144.
WilliamsPAHarderJMFoxworthNE, et al.Nicotinamide and WLDS act together to prevent neurodegeneration in glaucoma. Front Neurosci2017; 11: 1–10.
145.
AlbannaWKotliarKLukeJN, et al.Non-invasive evaluation of neurovascular coupling in the murine retina by dynamic retinal vessel analysis. PLoS One2019; 13: 1–14.
146.
RivaCELogeanEFalsiniB.Visually evoked hemodynamical response and assessment of neurovascular coupling in the optic nerve and retina. Prog Retin Eye Res2005; 24: 183–215.
147.
ChouTHToft-NielsenJPorciattiV.Adaptation of retinal ganglion cell function during flickering light in the mouse. Sci Rep2019; 9: 1–7.
148.
BullNDJohnsonTvWelsaparG, et al.Use of an adult rat retinal explant model for screening of potential retinal ganglion cell neuroprotective therapies. Invest Ophthalmol Vis Sci2011; 52: 3309–3320.
149.
SappingtonRMCarlsonBJCrishSD, et al.The microbead occlusion model: a paradigm for induced ocular hypertension in rats and mice. Invest Ophthalmol Vis Sci2010; 51: 207–216.
150.
CameronEGXiaXGalvaoJ, et al.Optic Nerve Crush in Mice to Study Retinal Ganglion Cell Survival and Regeneration. Bio Protoc2020; 10: 1–15.
de MoraesCGJohnSWMWilliamsPA, et al.Nicotinamide and pyruvate for neuroenhancement in open-angle glaucoma: a phase 2 randomized clinical trial. JAMA Ophthalmol2022; 140: 11–18.
153.
LeungCKSRenSTChanPPM, et al.Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial. Trials2022; 23: 1–10.
154.
HwangESSongSB.Possible adverse effects of high-dose nicotinamide: Mechanisms and safety assessment. Biomolecules2020; 10: 1–21.
155.
HorsmanMRHoyerMHonessDJ, et al.Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy. Radiother Oncol1993; 27: 131–139.
156.
ChengSCYoungDOHuangY, et al.A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol2008; 3: 1131–1138.
157.
ShahbazianHMohtashamiAZGhorbaniA, et al.Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial. Nefrologia2011; 31: 58–65.
158.
GaleEABingleyPJEmmettCL,et al.European Nicotinamide diabetes intervention trial (ENDIT) group. European nicotinamide diabetes intervention trial (ENDIT): a randomised controlled trial of intervention before the onset oftype 1 diabetes. Lancet [Internet]2004; 363: 925–931. Available from: www.thelancet.com
159.
MackayDHathcockJGuarneriE.Niacin: chemical forms, bioavailability, and health effects. Nutr Rev2012; 70: 357–366.
160.
SchultzNLopezESaleh-GohariN, et al.Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res2003; 31: 4959–4964.
161.
CefleKUcurAGuneyN, et al.Increased sister chromatid exchange frequency in young women with breast cancer and in their first-degree relatives. Cancer Genet Cytogenet2006; 171: 65–67.
162.
BittermanKJAndersonRMCohenHY, et al.Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast Sir2 and human SIRT1. J Biol Chem2002; 277: 45099–45107.
163.
SunWPZhaiMZLiD, et al.Comparison of the effects of nicotinic acid and nicotinamide degradation on plasma betaine and choline levels. Clin Nutr2017; 36: 1136–1142.
164.
WinterSLBoyerJL.Hepatic toxicity from large doses of vitamin B3 (nicotinamide). N Engl J Med1973;2 89: 1180–1182.
165.
MahmoudYIMahmoudAA.Role of nicotinamide (vitamin B3) in Acetaminophen-induced changes in rat liver: nicotinamide effect in Acetaminophen-damged liver. Exp Toxicol Pathol2016; 68: 345–354.
166.
TianYJLuoNChenNN, et al.Maternal nicotinamide supplementation causes global DNA hypomethylation, uracil hypo-incorporation and gene expression changes in fetal rats. Br J Nutr2014; 111: 1594–1601.
167.
MartensCRDenmanBAMazzoMR, et al.Chronic nicotinamide riboside supplementation is well-Tolerated and elevates NAD+ in healthy middle-Aged and older adults. Nat Commun2018; 9: 1–11.
168.
DollerupOLChristensenBSvartM, et al.A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr2018; 108: 343–353.
169.
AirhartSEShiremanLMRislerLJ, et al.An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLoS One2017; 12: 1–17.
170.
DolopikouCFKourtzidisIAMargaritelisN v, et al.Acute nicotinamide riboside supplementation improves redox homeostasis and exercise performance in old individuals: a double-blind cross-over study. Eur J Nutr2020; 59: 505–515.
171.
DellingerRWSantosSRMorrisM, et al.Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. NPJ Aging Mech Dis2017; 3: 1–9.
172.
ConzeDBCrespo-BarretoJKrugerC L.Safety assessment of nicotinamide riboside, a form of vitamin B3. Hum Exp Toxicol2016; 35: 1149–1160.
ConzeDBrennerCKrugerCL.Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Sci Rep2019; 9: 1–13.
